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Abstract  
 
Tumours of the anterior pituitary can manifest from all endocrine cell types but the 
mechanisms for determining their specification are not known. The Hippo kinase 
cascade is a crucial signalling pathway regulating growth and cell fate in numerous 
organs. There is mounting evidence implicating this in tumour formation, where it is 
emerging as an anti-cancer target. We previously demonstrated activity of the Hippo 
kinase cascade in the mouse pituitary and nuclear association of its effectors 
YAP/TAZ with SOX2-expressing pituitary stem cells. Here we sought to investigate 
whether these components are expressed in the human pituitary and if they are 
deregulated in human pituitary tumours. Analysis of pathway components by 
immunofluorescence reveals pathway activity during normal human pituitary 
development and in the adult gland. Poorly differentiated pituitary tumours (null cell 
adenomas, adamantinomatous craniopharyngiomas (ΑCPs) and papillary 
craniopharyngiomas (PCPs)), displayed enhanced expression of pathway effectors 
YAP/TAZ. In contrast, differentiated adenomas displayed lower or absent levels. 
Knock-down of the kinase-encoding Lats1 in GH3 rat mammosomatotropinoma cells 
suppressed Prl and Gh promoter activity following an increase in YAP/TAZ levels. In 
conclusion, we have demonstrated activity of the Hippo kinase cascade in the human 
pituitary and association of high YAP/TAZ with repression of the differentiated state 
both in vitro and in vivo. Characterisation of this pathway in pituitary tumours is of 
potential prognostic value, opening up putative avenues for treatments. 
 
Keywords: Hippo signalling, pituitary tumour, YAP, TAZ 
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Introduction 
 
The Hippo kinase cascade is a crucial conserved signalling pathway regulating organ 
growth across diverse species, through the control of cell proliferation, apoptosis and 
differentiation during development (Zhao et al. 2011). This phosphorylation cascade 
in mammals includes core kinases MST1/2 (a.k.a. STK3/4, orthologues of Drosophila 
Hippo) that activate Large tumour suppressor homologs 1 and 2 (LATS1/2), which in 
turn phosphorylate and inhibit the activation of transcriptional co-activators Yes-
associated protein (YAP), and WW domain containing transcription factor 
(TAZ/WWTR1), the major effectors of the cascade. YAP/TAZ act as co-activators to 
TEAD transcription factors (TEA domain family members 1-4) (Zhao et al. 2011). 
Nuclear YAP/TAZ are thus associated with low kinase activity and the promotion of 
growth, inhibition of apoptosis and the stem cell state, whilst cytoplasmic and 
phosphorylated YAP/TAZ are associated with active kinases and growth restriction. 
Deregulation of the mammalian Hippo signalling components has been implicated in 
the formation of tumours and cancers, with loss of MST1/2, LATS1/2, SAV, or 
MOB1 resulting in the development of different tumour types in mouse models (Mo 
et al. 2014). Furthermore, elevated levels and nuclear localisation of YAP and/or TAZ 
has been reported in a wide array of human cancers including hepatocellular 
carcinoma (HCC), prostate cancer, colorectal carcinoma (CRC), non-small cell lung 
cancer (NSCLC), ovarian cancer, clear cell renal carcinoma (ccRCC), pancreatic 
carcinoma, oesophageal squamous cell carcinoma, urothelial carcinoma of the 
bladder, and skin basal cell carcinoma (Zanconato et al. 2016).  
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Pituitary tumours account for 10% to 15% of intracranial neoplasms (Molitch 2017). 
Although in general they are considered benign tumours, an aggressive or invasive 
behaviour is not uncommon (Di Ieva et al. 2014). Hormonal secreting (functioning) 
pituitary tumours are commonly detected due to the clinical syndromes caused by 
hormonal hypersecretion (Chanson et al. 2015). Non-functioning subtypes are 
clinically challenging because they present at a later stage with local mass effects or 
hypopituitarism, as do craniopharyngiomas, both the adamantinomatous (ACP) and 
papillary (PCP) types. During the last years, progress has been made on the 
identification of mechanisms involved in anterior pituitary cell transformation and 
tumourigenesis; oncogene activation, tumour suppressor gene inactivation, 
epigenetic changes, and microRNA deregulation have all been shown to contribute 
to the initiation of pituitary tumours (Marques & Korbonits 2017). Recently, the 
isolation of cell subpopulations with stem-like characteristics was reported from 
human somatotropinomas and non-functioning pituitary adenomas (NFPAs), 
describing expression of stem cell markers (OCT4, SOX2, CD133, Nestin), sustained 
proliferation and a persistent undifferentiated compartment (Würth et al. 2016). There 
is evidence for a role of the Hippo signalling cascade in pituitary gland 
pathophysiology. Mice deficient for Lats1 (Lats1
-/-
) present with hyperplasia of the 
anterior pituitary lobe, but reduced secretion of hormones such as LH, PRL and GH 
(St John et al. 1999). We recently mapped for the first time the activity of the Hippo-
YAP/TAZ pathway in the murine pituitary during development and postnatal stages, 
and revealed an association of active Hippo effectors (i.e. nuclear YAP/TAZ 
localisation) with the uncommitted pituitary stem cells expressing SOX2 (Lodge et al. 
2016).  
 
Page 5 of 33
6 
 
Considering the involvement of the Hippo kinase cascade in tumourigenesis, our 
observations in the murine gland prompted us to examine the expression patterns of 
YAP and TAZ in the human normal pituitary and pituitary tumours. Herein we show 
for the first time that these proteins are expressed during human pituitary 
development as well as in the normal adult gland. YAP and TAZ were highly 
expressed in subsets of non-secreting pituitary tumours (null cell, ACP and PCP), but 
not in differentiated tumours. Activating this pathway in vitro by knocking down 
Lats1, decreased anterior pituitary hormone synthesis, further supporting a role for 
this cascade in repressing endocrine differentiation. Altogether, our data indicate a 
previously unappreciated involvement of the Hippo pathway in human pituitary 
differentiation, growth and tumour formation. 
 
 
Materials and Methods  
 
Tissue specimens 
All procedures performed were in accordance with the ethical standards of the 
institutional research committee (King’s College Research Ethics Committee (REC), 
approval number LRS-15/16-2126) and with the 1964 Helsinki declaration and its 
later amendments or comparable ethical standards. Anonymised archival FFPE 
specimens of five ACP (Andoniadou et al. 2012) and six PCP (Haston et al. 2017) 
were identified in the local pathology archive, through the Childhood’s Cancer and 
Leukaemia Group Tissue Bank and BRAIN UK. The study also included ten null cell 
pituitary tumours, 16 prolactinomas, one PRL-secreting carcinoma (Winkelmann et 
al. 2002), 18 corticotropinomas and 10 somatotropinomas. Examples of confirmatory 
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testing for these cohorts are provided in Supplementary Figure 2. Fetal pituitary tissue 
(two samples at 17 weeks and one sample at 14 weeks corrected gestational age) was 
accessed through the Human Developmental Biology Resource (HDBR). Normal 
human pituitary glands were obtained from the School of Medicine, Lille, France 
from people who donated their body to science (two male, two female, ages 77-89 
years old); permission to use human tissues was obtained from the French Agency for 
Biomedical Research (Agence de la Biomédecine, Saint-Denis la Plaine, France, 
protocol no. PFS16-002). Ischaemia time until fixation ranged between 8-39 hours. 
Pituitaries were fixed in 4% paraformaldehyde at 4°C for a minimum of 48 hours 
before processing for paraffin embedding.  
 
Immunofluorescence  
Samples were dewaxed in Histo-Clear
TM
 (National Diagnostics) twice for 10 min, 
followed by rehydration through a descending ethanol series. Antigen retrieval was 
carried out in citrate-based Declere™ unmasking solution (Cell Marque) in a 
Decloaking chamber NXGEN (Menarini Diagnostics) using the 110ºC antigen 
retrieval protocol. Following blocking for one hour in TNB blocking buffer [0.1M 
Tris-HCl pH7.5, 0.15M NaCl, 0.5% Blocking Reagent (FP1020, Perkin Elmer), 
samples were incubated overnight in primary antibodies at 4°C in TNB at the 
following dilutions: YAP (Cell Signaling Technology Cat. No. 4912, 1:1000), pYAP 
(S127) (Cell Signaling Technology Cat. No. 4911 1:1000), TAZ (Atlas Antibodies 
HPA007415, 1:2000), and SOX2 (Abcam ab97959, 1:2000). The following day, 
slides were washed in Tris-NaCl-Tween (TNT) buffer (0.1M Tris-HCl, pH7.5, 0.15M 
NaCl, 0.05% Tween-20) and incubated in species-specific biotinylated secondary 
antibodies (1:500, Abcam) diluted in TNB for 1 hour at room temperature. Following 
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washes in TNT, slides were incubated in ABC solution (Vector Laboratories PK-
6100) for 30 min in the dark and in TSA-Cy3 diluted in TSA Stock Solution (Perkin 
Elmer NEL760001) for 10 min at room temperature. Subsequently, slides were 
washed and incubated in Hoechst labeling solution for 30 minutes at room 
temperature. After a final wash, they were mounted with soft-set mounting medium 
(Vector Laboratories, H1000). Immunofluorescence staining was assessed as follows: 
Type A: high levels of both YAP/TAZ, frequent nuclear staining; Type B: robust 
levels of TAZ with frequent nuclear staining and moderate levels of YAP with 
occasional nuclear staining; Type C: moderate levels of YAP/TAZ, predominantly 
cytoplasmic, in over 50% of the tumour; Type D: low levels of YAP/TAZ, 
predominantly cytoplasmic, between 20-50% of tumour; Type E: absent YAP/TAZ 
staining or low levels in under 20% of the tumour. 
 
Cell culture, transfection and luciferase assays  
GH3 cells (American Type Culture Collection) were cultured in 10% fetal calf serum 
Dulbeco’s modified Eagle medium (DMEM) supplemented with 2.2 g/L NaHCO3, 10 
mM HEPES, 2 nM Glutamine and 10
5
 U/L penicillin-streptomycin. Cell culture 
materials were from Life Technologies (Karlsruhe, Germany), Nunc (Wiesbaden, 
Germany) and Sigma-Aldrich (St. Louis, MO, USA). Cells were transfected with 
SuperFect (Qiagen) following the manufacturer’s instructions. siRNA were against rat 
Lats1 (OriGene and Santa Cruz Biotechnology); a mix of scrambled non-specific 
siRNA was used as control. The GH and PRL promoter reporter vectors have the 
proximal (_593) rat Gh promoter and rat Prl promoter respectively upstream to the 
luciferase gene (both kind gifts of A. Gutierrez-Hartmann, University of Colorado, 
Denver, CO). After transfection, cells were left for 48 hours in low serum (2% FCS) 
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DMEM, before being treated and/or assayed. The transfection efficacy was 
determined by cotransfection with the RSV-β-gal construct and results are presented 
as luciferase: β-galactosidase activity ratio. Each experiment was done in triplicate.  
Cell proliferation was determined 48 hours after transfection using the WST-1 
colorimetric assay (Roche Molecular Biochemicals, Mannheim, Germany) following 
the manufacturer’s instructions. 
 
Immunoblotting 
GH3 cells were lysed in ice-cold RIPA lysis buffer supplemented with protease and 
phosphatase inhibitors cocktail (Roche). Proteins were separated by polyacrylamide 
gel electrophoresis and blotted using standard procedures (BioRad). Primary 
antibodies were against LATS1 (C66B5, #3477), YAP/TAZ (D24E4, #8418) and 
phosphorylated pYAP(S127) (D9W2I, #13008) (all rabbit mAb, Cell Signaling), and 
β-actin (mouse mAb, Chemicon).  Anti-rabbit or anti-mouse horseradish peroxidase-
conjugated secondary antibodies were used (Cell Signaling) and signal was developed 
with enhanced chemiluminescent solution (Roche). Each experiment was carried out 
in duplicate. 
 
 
Results 
 
YAP and TAZ are expressed in human fetal and adult pituitaries 
To investigate the Hippo pathway activity in the human pituitary during development 
and adulthood we determined the expression of its downstream effectors YAP and 
TAZ. In the human fetal pituitary at 17 weeks, high expression of both was observed 
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in the posterior and anterior lobe within the epithelial remnants of Rathke’s pouch 
(marginal zone epithelium, MZE) that highly express the stem cell marker SOX2; the 
main body of the anterior lobe presented with moderate YAP and TAZ 
immunoreactivity (Figure 1b). Both proteins mainly localised in the nucleus as well as 
the cytoplasm (arrowheads). The nuclear localisation was more prominent in the case 
of TAZ (arrowheads) throughout the MZE, similar to SOX2 expression. Nuclear 
immunoreactivity in the MZE was also observed for YAP, albeit to a lesser extent. 
The core Hippo kinases LATS1/2 phosphorylate YAP on serines S61, S109, S127, 
S164 and S381, leading to its inactivation through cytoplasmic retention (S127) and 
degradation (Zhao et al. 2007, 2010). To determine if the kinases are active, we 
performed immunostaining against pYAP(S127), and observed strong cytoplasmic as 
well as nuclear localisation in both the epithelium and parenchyma (arrowheads), 
suggesting that LATS kinases are active during embryonic development. These 
observations were confirmed in further fetal pituitary samples at 17 and 14 weeks of 
gestation (Supplementary Figure 1). To determine if expression of YAP and TAZ 
persists in the adult pituitary, we analysed immunoreactivities in adult pituitaries of 
advanced age (n=4) (Figure 1c). Strong nuclear TAZ staining persisted both in cells 
of the MZE and parenchyma, following the expression pattern of SOX2. YAP 
immunoreactivity was predominantly cytoplasmic in the MZE, while nuclear staining 
was occasionally observed in the parenchyma. Staining against pYAP(S127) persisted 
in the adult pituitary indicating the presence of an active Hippo cascade during 
adulthood. In summary, YAP and TAZ are expressed in the developing and adult 
human pituitary, where LATS kinases are active. 
 
Expression of YAP and TAZ in pituitary tumours  
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We next sought to determine the expression patterns of YAP and TAZ in human 
pituitary tumours. In human craniopharyngiomas, which are composed mainly of non-
endocrine cells, the expression of SOX2/SOX9 (both progenitor/stem cell markers) 
has been well documented in both the papillary type (PCP), harbouring MAPK 
pathway mutations as well as the adamantinomatous type (ACP) that harbour 
CTNNB1 mutations (encoding β-Catenin) (Hölsken et al. 2014; Thimsen et al. 2017; 
Haston et al. 2017). Strong YAP and TAZ stainings were observed in all PCPs tested 
and were predominantly nuclear in the basal cells and suprabasal squamous 
epithelium (asterisks in Figure 2a), described to robustly express SOX2 (Haston et al. 
2017)(Figure 2a and Table 1). Strong nuclear staining for YAP and TAZ was 
observed in all five ACPs, both in whorl-like formations described to accumulate β-
catenin (asterisks in Figure 2b) as well as in the palisading epithelium (arrows in 
Figure 2b). Null cell pituitary tumours do not show immunoreactivity for any of the 
pituitary hormones, although there is evidence that in their majority they express 
lineage-specific transcription factors (Mete & Lopes 2017; Nishioka H 2018). YAP 
and TAZ expression was variable and was subdivided into three different groups 
based on a semiquantitative scoring system as described in the methods (Table 1, 
Figure 2c). Four out of 10 null cell tumours displayed high immunoreactivity 
consistent with Type A, three were identified as Type B and three as Type C. There 
was no obvious correlation of the immunohistochemical data to age at presentation, 
rate of recurrence, Ki-67 index or p53 levels, although the study cohort is low for this 
to be accurately determined (Table 2).  
 
Altogether our data from normal pituitaries and pituitary tumours suggest that high 
levels of nuclear YAP/TAZ are associated with a more uncommitted state in the 
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anterior pituitary, consistent with previous mouse data (Lodge et al. 2016). To explore 
this hypothesis further, we extended our study to include 16 prolactinomas, the most 
common type of secreting pituitary tumours, 10 somatotropinomas and 18 
corticotropinomas. YAP and TAZ immunoreactivities were observed at much lower 
levels than in craniopharyngiomas and null cell pituitary adenomas.  Based on our 
semiquantitative scoring system, two types of staining were detected in 
prolactinomas: Type D, characterised by cytoplasmic YAP/TAZ in 20-50% of tumour 
cells, and Type E, characterised by absence of staining or weak cytoplasmic in less 
than 20% of the tumour (Figure 3a). In the majority of prolactinomas (11 out of 16), 
YAP/TAZ staining was classified as Type E, where most of the tissue was negative 
for YAP and TAZ. In corticotropinomas staining ranged from Type B to Type D 
(Supplementary Figure 3a) and in somatotropinomas from Type B to Type E 
(Supplementary Figure 3b). Results are summarised in Table 1. To determine if 
YAP/TAZ become elevated in aggressive/invasive tumours, we analysed their 
expression in one PRL-secreting carcinoma. This tumour appeared entirely negative 
for both proteins (Figure 3b, Region 1) and only one area included cells with nuclear, 
but not cytoplasmic TAZ staining and cytoplasmic YAP immunoreactivity, similar to 
adult normal anterior pituitary (Figure 3b, Region 2). Therefore, YAP/TAZ levels are 
low in differentiated tumours, and in the single malignant prolactinoma sample 
analysed. In summary, robust expression levels and more abundant nuclear 
localization of YAP/TAZ are seen in non-secreting tumour types, harbouring a less 
differentiated cellular component, compared to tumours composed of differentiated 
cells. 
 
Lats1 knockdown reduces Gh and Prl promoter activity in GH3 cells in vitro  
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Our observations of a robust decrease or loss of YAP/TAZ in hormone-secreting 
pituitary tumours, compared to normal pituitary and non-secreting tumours, suggest a 
role for the Hippo kinases in promoting a hormone-secreting phenotype and/or 
repressing a progenitor/stem-like state. To this end, employing RNA interference, we 
inhibited LATS1, since it directly phosphorylates and marks YAP and TAZ for 
cytoplasmic retention and degradation. Knock-down of Lats1 in rat 
mammosomatotrophinoma GH3 cells reduced YAP phosphorylation at S127 and 
increased YAP and TAZ protein levels (Figure 4a). This was accompanied by 
significant suppression of basal Gh and Prl promoter activity (Figure 4b). Lats1 
inhibition also reduced activation of the Gh promoter following stimulation with 
forskolin compared to scrambled siRNA control (Figure 4c). Lats1 inhibition did not 
affect GH3 cell proliferation (Figure 4d). These in vitro findings indicate that 
deregulation of the Hippo pathway may repress pituitary hormone synthesis and 
compromise the pituitary cell response to physiological hormonal stimuli. 
 
 
Discussion 
 
Initially described in Drosophila, the Hippo pathway is now recognised as one of the 
most conserved molecular pathway in all metazoans, which is highly involved in fine-
tuning of organ size through inhibition of proliferation and promotion of 
differentiation and cell death (Yu et al. 2015) with a contribution to tumourigenesis 
and cancer development (Mo et al. 2014). The present study demonstrates for the first 
time the expression patterns of two major downstream effectors of the Hippo 
pathway, YAP and TAZ, in the fetal and adult normal pituitary gland and provides 
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evidence of Hippo pathway activity during embryonic development that persists into 
adulthood. Interestingly the YAP/TAZ expression pattern is reminiscent of SOX2 in 
pituitary stem/progenitor cells recapitulating our previous findings in mice and 
indicating a potential link of the Hippo pathway to the stem/progenitor cell state 
(Lodge et al. 2016).  
 
We investigated the expression of YAP/TAZ in three types of non-secreting/non-
differentiated pituitary tumours: null-cell adenomas, ACPs and PCPs. YAP and TAZ 
were highly expressed in all ACP and PCP tumours. The expression pattern was 
nuclear and occasionally cytoplasmic in craniopharyngiomas that harbour known 
genetic mutations in CTNNB1 or BRAF, and was located to well-characterised tumour 
compartments known to express progenitor markers. ACP tumourigenesis is mainly 
driven by mutations in the CTNNB1 gene that encodes for β-catenin, the central 
regulator of the WNT pathway (Sekine et al. 2002). Gain-of-function alleles of BRAF 
activate the RAS-RAF-MEK-ERK pathway and may drive tumourigenesis in PCPs, 
which appear almost exclusively in adults (Brastianos et al. 2014; Larkin et al 2014) . 
In support of this, a mouse model overexpressing BRAF V600E in mouse pituitary 
precursors leads to increased proliferation of SOX2 stem cells and a block in 
differentiation (Haston et al. 2017). Interestingly both pathways were described to 
crosstalk with the Hippo signalling cascade. YAP forms a transcriptional complex 
with β-catenin that is required for tumour transformation and survival (Rosenbluh et 
al. 2012). When core Hippo kinases are active, YAP/TAZ are degraded or 
sequestered in the cytosol where they limit WNT-β-catenin signalling (Varelas et al. 
2010). In contrast, WNT activation induces YAP/TAZ translocation to the nucleus 
and activation (Attisano & Wrana 2013; Azzolin et al. 2014). Similarly, RAS 
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signalling activates YAP and there is evidence for involvement of YAP in tumour 
resistance to pharmacological RAF-MEK inhibition (Reddy & Irvine 2013; Lin et al. 
2015; You et al. 2015).  
 
YAP and TAZ were also highly expressed in null cell pituitary tumours, but at 
variable levels. Similar to craniopharyngiomas, they also often displayed strong 
nuclear staining. There is mounting evidence that TAZ and YAP nuclear localisation 
correlates with metastatic potential, low response to treatment and worse patient 
outcome in several solid tumours (Zanconato et al. 2016). The relatively small 
number of cases did not allow us to correlate the pattern of staining with histological 
or clinical data but also recurrence may happen even after years of remission. Based 
on the recent WHO classification for pituitary adenomas, clinical aggressiveness is 
assessed by several clinical parameters such as tumour invasion (by MRI studies 
and/or intraoperative impression), in addition to mitotic count and Ki-67 index (Lopes 
MBS 2017). Whether YAP/TAZ may directly promote an oncogenic phenotype in the 
pituitary through activation of genes involved in proliferation/survival/invasion 
directly or secondary to other genetic defects like the ones found in ACP and PCP, is 
an intriguing possibility that remains to be explored.  
 
In contrast to the majority of the non-differentiated tumours that often displayed 
strong nuclear staining, YAP/TAZ expression in the hormone secreting prolactinomas 
was very low or completely absent, suggesting that in the human pituitary YAP/TAZ 
expression may be associated with a shift from high to low secretory potential and 
therefore a less differentiated state. Indeed, our in vitro model showed that increasing 
YAP and TAZ expression in lactosomatotroph GH3 cells, by knocking down their 
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upstream regulator Lats1, dramatically reduces PRL as well as GH synthesis without 
affecting cell proliferation. Interestingly in the case of GH, the effect is prominent 
also after cAMP/PKA stimulation with forskolin. These data reflect the observations 
in the Lats1
-/- 
mice, which presented with low PRL and GH levels despite their 
hyperplastic pituitaries (St John et al. 1999). YAP/TAZ were shown to repress the 
differentiated state in other tissues (Lee et al. 2016; Yi et al. 2016; Cotton et al. 
2017).  Our data further support this notion and suggest that high levels of YAP/TAZ 
are associated with repression of hormone production and therefore a non-
differentiated/progenitor state.  
 
Treatment of pituitary tumours primarily relies on reducing hormone hypersecretion 
and its effects, decreasing the tumour mass and treating for any hormone deficiencies 
resulting from damage of normal pituitary tissue. Hippo signalling components and 
particularly YAP/TAZ have recently become attractive targets for new anti-cancer 
treatments (Johnson & Halder 2013; Nakatani et al. 2016). Our finding of increased 
expression of YAP/TAZ in non-secreting pituitary tumours reveals a previously 
unsuspected pathogenetic mechanism. Better understanding and targeting the Hippo 
signalling cascade could introduce novel improved treatments for these intriguing and 
hard to manage tumours. 
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Figure Legends 
 
Figure 1. YAP and TAZ are expressed in the human pituitary. (a) Haematoxylin and 
Eosin staining of sequential frontal sections of human fetal and adult pituitaries. Asterisks 
denote cysts between the anterior and posterior pituitary. (b) Frontal sections of fetal 
pituitaries at 17 weeks were stained for SOX2 (pituitary stem/progenitor marker), total TAZ, 
total YAP and pYAP(S127) marking inactive YAP. Arrowheads indicate examples of cells 
with nuclear protein. (c) Localisation of SOX2, TAZ, YAP and pYAP proteins in the adult 
anterior pituitary. Arrowheads indicate examples of cells with nuclear protein, and examples 
of cytoplasmic localisation for pYAP in (b). PL, posterior lobe; AL, anterior lobe; MZE, 
marginal zone epithelium; Par, parenchyma. 
 
Figure 2. Expression of YAP and TAZ in non-secreting pituitary tumours. (a) 
Representative immunostaining against TAZ, YAP and pYAP(S127) in samples of papillary 
craniopharyngioma (PCP). Arrowheads denote examples of nuclear staining; asterisks, the 
suprabasal squamous epithelium. (b) Representative immunostaining against TAZ, YAP and 
pYAP(S127) in samples of adamantinomatous craniopharyngioma (ACP). Arrowheads 
indicate nuclear staining; arrows, the palisading epithelium; asterisks, characteristic whorl-
like cluster cells. (c) Immunostaining against TAZ, YAP and pYAP(127) on null cell 
pituitary adenomas, showing representative staining from tumours classified as Type A, B 
and C. Arrowheads indicate nuclear staining. Scale bars 100µm. 
 
Figure 3. Expression of YAP and TAZ in prolactin-secreting pituitary tumours. (a) 
Representative immunostaining against TAZ, YAP and pYAP(S127) in prolactinoma 
samples. Based on the staining patterns tumours were classified as Type D or Type E. (b) 
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Expresion of TAZ and YAP in two regions of a prolactin-secreting carcinoma. Scale bars 
100µm. 
 
Figure 4. LATS1 inhibition with RNA interference suppresses the promoter activities of 
anterior pituitary hormones. (a) GH3 cells were transfected with a scrambled siRNA 
(control) or four different siRNA against rat Lats1 for 48 hours. Immunoblot shows the 
knockdown efficacy and the impact of decreased LATS1 protein on YAP phosphorylation at 
Ser127 and total YAP and TAZ protein levels. (b) Effect of Lats1 knockdown on basal Prl 
and Gh promoter activity. Data are luciferase to β-galactosidase ratio, means±standard 
deviation of three experiments (each in triplicate) presented as percentage of scrambled 
control. RLA, relative luciferase activity. * P<0.05 to scrambled vehicle control. (c) Effect of 
Lats1 knockdown on forskolin-induced (10 µM, 6 hours treatment) Gh promoter activity. 
Data are means±standard deviation of three triplicates and presented as percentage of 
scrambled vehicle control. * P<0.05 and *** P< 0.001 versus scrambled vehicle control, # 
P<0.05 versus siLats1 vehicle control. Veh, vehicle - the carrier in which forskolin was 
diluted. (d) Lats1 knockdown does not affect cell proliferation (WST-1 colorimetric assay). 
Data are absorbance at OD450nm presented as percentage of scrambled siRNA control. 
 
Supplementary Figure 1. YAP and TAZ are expressed in human fetal pituitaries. (a) 
Haematoxylin and eosin staining of sequential frontal sections of human fetal pituitaries at 14 
and 17 weeks corrected gestational age. (b-c) Frontal sections of fetal pituitaries at 14 weeks 
(b) and 17 weeks (c) were stained for SOX2 (pituitary stem/progenitor marker), total TAZ, 
total YAP and pYAP(S127) marking inactive YAP. Arrowheads indicate examples of cells 
with nuclear protein. (c) Localisation of SOX2, TAZ, YAP and pYAP proteins in the adult 
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anterior pituitary. Arrowheads indicate examples of cells with nuclear protein. PL, posterior 
lobe; AL, anterior lobe; MZE, marginal zone epithelium; Par, parenchyma. 
 
Supplementary Figure 2. Confirmatory testing for the diagnosis of tumours.  
(a-b) Examples of confirmatory testing as part of the diagnosis of null cell adenoma, 
corticotropinoma, somatotropinoma and prolactinoma. (a) Haematoxylin and eosin staining, 
immunohistochemistry for FSH and SF1 on a null cell adenoma (top row) and a silent 
gonadotroph adenoma (bottom row) used as a positive control. (b) Examples of 
immunohistochemistry for specific hormones from two tumours of each cohort of 
corticotropinomas (ACTH), somatotropinomas (GH) and prolactinomas (PRL). All samples 
are counterstained with hematoxylin. Scale bars 50µm. 
 
Supplementary Figure 3. Expression of YAP and TAZ in secreting pituitary tumours. 
(a) Immunostaining against TAZ and YAP in samples of corticotropinoma showing 
representative staining from tumours classified as Types B, C and D. (b) Immunostaining 
against TAZ and YAP in samples of somatotropinoma showing representative staining from 
tumours classified as Types B, C, D and E. Arrowheads indicate nuclear staining; asterisk 
marks a blood vessel. Scale bars 100µm. 
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Table 1.  Classification of YAP and TAZ staining in pituitary tumours 
Tumour Type Classification Number TAZ YAP 
Normal Pituitary Type B 4 +++ n c ++ n c 
PCP Type A 6 ++++ n c 
++++ or +++ 
n c 
ACP Type A 5 ++++ n c 
++++ or +++ 
n c 
 
Null cell adenoma 
Type A 4 ++++ n c 
++++ or +++ 
n c 
Type B 4 +++ n c ++ n c 
Type C 2 ++ or +  c ++ or + c 
Corticotropinoma  
Type B 5 +++ n c ++ n c 
Type C 7 ++ or +  c ++ or + c 
Type D 6 + c + c 
Somatotropinoma 
Type B 2 +++ n c ++ n c 
Type C 2 ++ or +  c ++ or + c 
Type D 5 + c + c 
Type E 1 - - 
Prolactinoma 
Type D 11 + c + c 
Type E 5 - - 
 
ACP, adamantinomatous craniopharyngioma; PCP, papillary craniopharyngioma; +, 
positive staining; -, negative staining; n, nuclear; c, cytoplasmic.  
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Table 2. Related data for null cell pituitary adenomas 
 
Sample Type Histology Ki-67 
Notable 
Characteristics 
p53 
Status 
Age at 
Presentation Sex 
Null1 A 
null cell 
adenoma 2-3%  - 46 F 
Null2 A 
null cell 
adenoma 3-5%  2-3% 27 F 
Null3 A 
null cell 
adenoma 3-5%  >1% 48 F 
Null4 A 
null cell 
adenoma < 3%  - 36 F 
Null5 B 
null cell 
adenoma 5-7% recurrence < 1% 41 F 
Null6 B 
null cell 
adenoma 2-3%  - 73 F 
Null7 B 
null cell 
adenoma 2-3%  - 31 F 
Null8 B 
null cell 
adenoma 
1-2% 
  - 49 F 
Null9 C 
null cell 
adenoma < 2% 
necrotic 
areas - 48 M 
Null10 C 
null cell 
adenoma 2.5%  - 33 F 
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YAP and TAZ are expressed in the human pituitary. (a) Haematoxylin and Eosin staining of sequential frontal 
sections of human fetal and adult pituitaries. Asterisks denote cysts between the anterior and posterior 
pituitary. (b) Frontal sections of fetal pituitaries at 17 weeks were stained for SOX2 (pituitary 
stem/progenitor marker), total TAZ, total YAP and pYAP(S127) marking inactive YAP. Arrowheads indicate 
examples of cells with nuclear protein. (c) Localisation of SOX2, TAZ, YAP and pYAP proteins in the adult 
anterior pituitary. Arrowheads indicate examples of cells with nuclear protein, and examples of cytoplasmic 
localisation for pYAP in (b). PL, posterior lobe; AL, anterior lobe; MZE, marginal zone epithelium; Par, 
parenchyma.  
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Expression of YAP and TAZ in non-secreting pituitary tumours. (a) Representative immunostaining against 
TAZ, YAP and pYAP(S127) in samples of papillary craniopharyngioma (PCP). Arrowheads denote examples of 
nuclear staining; asterisks, the suprabasal squamous epithelium. (b) Representative immunostaining against 
TAZ, YAP and pYAP(S127) in samples of adamantinomatous craniopharyngioma (ACP). Arrowheads indicate 
nuclear staining; arrows, the palisading epithelium; asterisks, characteristic whorl-like cluster cells. (c) 
Immunostaining against TAZ, YAP and pYAP(127) on null cell pituitary adenomas, showing representative 
staining from tumours classified as Type A, B and C. Arrowheads indicate nuclear staining. Scale bars 
100µm.  
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Expression of YAP and TAZ in prolactin-secreting pituitary tumours. (a) Representative immunostaining 
against TAZ, YAP and pYAP(S127) in prolactinoma samples. Based on the staining patterns tumours were 
classified as Type D or Type E. (b) Expresion of TAZ and YAP in two regions of a prolactin-secreting 
carcinoma. Scale bars 100µm.  
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LATS1 inhibition with RNA interference suppresses the promoter activities of anterior pituitary hormones. (a) 
GH3 cells were transfected with a scrambled siRNA (control) or four different siRNA against rat Lats1 for 48 
hours. Immunoblot shows the knockdown efficacy and the impact of decreased LATS1 protein on YAP 
phosphorylation at Ser127 and total YAP and TAZ protein levels. (b) Effect of Lats1 knockdown on basal Prl 
and Gh promoter activity. Data are luciferase to β-galactosidase ratio, means±standard deviation of three 
experiments (each in triplicate) presented as percentage of scrambled control. RLA, relative luciferase 
activity. * P<0.05 to scrambled vehicle control. (c) Effect of Lats1 knockdown on forskolin-induced (10 µM, 
6 hours treatment) Gh promoter activity. Data are means±standard deviation of three triplicates and 
presented as percentage of scrambled vehicle control. * P<0.05 and *** P< 0.001 versus scrambled vehicle 
control, # P<0.05 versus siLats1 vehicle control. Veh, vehicle - the carrier in which forskolin was diluted. (d) 
Lats1 knockdown does not affect cell proliferation (WST-1 colorimetric assay). Data are absorbance at 
OD450nm presented as percentage of scrambled siRNA control.  
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